273 related articles for article (PubMed ID: 31027840)
21. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
22. Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe.
Vončina L; Strbad T; Fürst J; Dimitrova M; Kamusheva M; Vila M; Mardare I; Hristova K; Harsanyi A; Atanasijević D; Banović I; Bobinac A
Appl Health Econ Health Policy; 2021 Nov; 19(6):915-927. PubMed ID: 34553334
[TBL] [Abstract][Full Text] [Related]
23. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
24. [What is an efficient health intervention in Spain in 2020?].
Sacristán JA; Oliva J; Campillo-Artero C; Puig-Junoy J; Pinto-Prades JL; Dilla T; Rubio-Terrés C; Ortún V
Gac Sanit; 2020; 34(2):189-193. PubMed ID: 31558385
[TBL] [Abstract][Full Text] [Related]
25. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.
Maynou L; Cairns J
Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736
[TBL] [Abstract][Full Text] [Related]
26. Towards Integrated Health Technology Assessment for Improving Decision Making in Selected Countries.
Oortwijn W; Determann D; Schiffers K; Tan SS; van der Tuin J
Value Health; 2017 Sep; 20(8):1121-1130. PubMed ID: 28964444
[TBL] [Abstract][Full Text] [Related]
27. Reflections on the evolution of health technology assessment in Europe.
Sorenson C; Chalkidou K
Health Econ Policy Law; 2012 Jan; 7(1):25-45. PubMed ID: 22221927
[TBL] [Abstract][Full Text] [Related]
28. STAKEHOLDER INVOLVEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS IN LATIN AMERICA.
Pichon-Riviere A; Soto N; Augustovski F; Sampietro-Colom L
Int J Technol Assess Health Care; 2018 Jan; 34(3):248-253. PubMed ID: 29888698
[TBL] [Abstract][Full Text] [Related]
29. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
Stafinski T; Glennie J; Young A; Menon D
Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
[TBL] [Abstract][Full Text] [Related]
30. INTRODUCTION OF HEALTH TECHNOLOGY ASSESSMENT FOR MEDICINES IN SLOVAKIA.
Tesar T; Hloska A; Wawruch M; Lehocka L; Snopkova M; Masarykova L
Int J Technol Assess Health Care; 2017 Jan; 33(3):345-349. PubMed ID: 28434416
[TBL] [Abstract][Full Text] [Related]
31. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
32. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
33. HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey.
García-Mochón L; Espín Balbino J; Olry de Labry Lima A; Caro Martinez A; Martin Ruiz E; Pérez Velasco R
Health Policy; 2019 Feb; 123(2):182-190. PubMed ID: 28420539
[TBL] [Abstract][Full Text] [Related]
34. Synergy between health technology assessments and clinical guidelines for multiple sclerosis.
Hogervorst MA; Vreman RA; Zawada A; Zielińska M; Dawoud DM; de Jong BA; Mantel-Teeuwisse AK; Goettsch WG
Clin Transl Sci; 2023 May; 16(5):835-849. PubMed ID: 36855929
[TBL] [Abstract][Full Text] [Related]
35. How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada.
Mills M; Kanavos P
Health Policy; 2022 Nov; 126(11):1130-1143. PubMed ID: 36050193
[TBL] [Abstract][Full Text] [Related]
36. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
Rand LZ; Kesselheim AS
J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
[TBL] [Abstract][Full Text] [Related]
37. Comparative Assessment of Reimbursement Recommendations by NICE and HAS for Oncology New Medicines Indicated for the Treatment of Solid Tumors from 2015 to 2021.
Trouiller JB; Laramée P
Med Decis Making; 2023; 43(7-8):961-972. PubMed ID: 37480275
[TBL] [Abstract][Full Text] [Related]
38. A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
Allen N; Liberti L; Walker SR; Salek S
Front Pharmacol; 2017; 8():384. PubMed ID: 28713265
[No Abstract] [Full Text] [Related]
39. Implementation Road Map of Health Technology Assessment in Middle-Income Countries: The Case of Jordan.
Almomani E; Alabbadi I; Fasseeh A; Al-Qutob R; Al-Sharu E; Hayek N; Tarawneh MR; Kaló Z
Value Health Reg Issues; 2021 Sep; 25():126-134. PubMed ID: 34015521
[TBL] [Abstract][Full Text] [Related]
40. Demonstrating the influence of HTA: INAHTA member stories of HTA impact.
Werkö SS; Merlin T; Lambert LJ; Fennessy P; Galán AP; Schuller T
Int J Technol Assess Health Care; 2020 Nov; 37():e8. PubMed ID: 33148373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
